Selling, general and administrative $44,939. Why do you need 45 million per quarter to market this drug? All you should need is 4 regional sales guys and a few inside sales. This is insane.
I just saw this on Twitter, This is amazing...
none of this matter, the total stake that Zognex has in ER market is .23%, the total market is significantly larger, it is just the Zogneix sales team is worthless. They need to start working on express scripts and get them to cover the formulation.
There is nothing to pump, they will lose $20+M this quarter. The sales of Zohydro is not growing fast enough to stem the losses of having to have 200 sales and marketing personnel.
That is not a jump, a jump would be 1275 to 5000, like the JAMA article said they are not even 0.25% of the ER perscriptions.
According to the article Zogenix sales team is inept: In July 2014, Zohydro ER’s sixth month of marketing, there were 3588 outpatient retail prescriptions dispensed. This represents 0.23% of the 1.6 million ER/LA opioid analgesic prescriptions and 0.02% of the nearly 18 million prescriptions dispensed for all opioid analgesics during the month.
Once you change the t-cells genetically they are no longer host cells. We all know GVHD is deadly so eventually you will see patients dying with CAR-T and FDA will halt the trials and ask for a plan to address that and that may not even be addressable. Juno already experienced patients dying with their small trial and you likely will see this happen again with Juno's large trial, and these guys will also likely experience the same.
You don't get it, according to the article both the control group and the drug groups had access to 6 doses on IR medication. Therefore if the majority of the drug group as well as majority of the control group took the rescue medication the drug is an utter failure because despite the superior analgesic effect of the drug group, the fact that they needed rescue medication with APAP, defeats the purpose of the drug and the drug would not be approvable for its APAP-free indication. Now if not majority, but a good portion of the drug group required rescue medication, if drug approved by the FDA, there would still be a need for zohydro ER in the market place because the patients on zohydro don't need rescue medication.
If the purdue drug requires rescue medication that contain APAP, doesn't that defeat the purpose of the drug?
The article I am reading says the patients were allowed to use up to 6 doses of rescue medication of 5m oxycodone per day. Can someone who have an access to the trial papers tell us if it is true?
The fact that the drug does not sell has no thing to do with the CEO, he already has 190 people in the commercial organization and the drug has already gotten so much publicity that every patient and doctor already knows about it. As far as I am concern even if gets rid of all of his sales staff, the drug will continue to sell at the current pace just because of the awareness caused by the media.. The fact is the drug itself has a limited market potential. Perhaps because there are not too many patients with bad livers at least not yet. Assuming they got 1225 perscrptions (as reported by someone on this board) on the second week of September it is not too hard to surmise that the scripts will grow over time and probably plateu around 3k prescriptions per week some times next year so they just have to adjust the cost structure to that run rate and focus on the other drug.